CG Oncology (NASDAQ: CGON) officer plans new sale after $7.95M August trade
CG Oncology (CGON) officer Ambaw Bellete filed a Form 144 notice to sell 5,762 shares of common stock, following a stock option exercise. Bellete has sold significant shares in recent months, including 100,000 shares on August 19, 2026, for $7.95M. Morgan Stanley Smith Barney LLC is the broker.
How this was made
The 30-second read
Why it matters
The filing indicates a modest new supply of CGON shares, but the amount is small relative to overall float, suggesting limited price impact unless followed by additional sales.
Market read
Primary disclosure of insider share sale; modest relevance for short‑term traders monitoring supply dynamics.
What to watch
Potential upcoming clinical data could offset any short‑term sell pressure.
Background
Form 144 disclosures are required for insiders planning to sell restricted shares; they provide early warning of possible supply increases.
Ticker impact
Form 144 filed by officer Ambaw Bellete shows a planned sale of 5,762 shares after a recent option exercise.
Minor downward pressure if shares hit the market.
The sale size is small relative to float; impact limited unless multiple insiders sell concurrently.
Market effects
None significant; biotech sector unchanged.
Limited to US micro‑cap investors.
Minimal.
Counterpoint
The insider sale may signal confidence if the officer retains a large position.
Key entities
- OfficerAmbaw Bellete
CG Oncology officer filing Form 144 for share sale.
- BrokerMorgan Stanley Smith Barney LLC
Broker handling the planned share sale.
.jpg&w=2048&q=75)